Traws Pharma (TRAW) to Post Earnings on Thursday

Traws Pharma (NASDAQ:TRAW) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.3350) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:30 AM ET.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.39. On average, analysts expect Traws Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Traws Pharma Trading Up 1.5%

Shares of NASDAQ TRAW opened at $0.54 on Tuesday. The stock has a market cap of $8.18 million, a P/E ratio of -0.32 and a beta of 1.57. The business’s fifty day simple moving average is $0.80 and its 200-day simple moving average is $1.42. Traws Pharma has a 12-month low of $0.43 and a 12-month high of $3.27.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP increased its position in Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after purchasing an additional 5,955 shares in the last quarter. Geode Capital Management LLC raised its holdings in Traws Pharma by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after buying an additional 18,213 shares during the period. State Street Corp acquired a new position in Traws Pharma during the fourth quarter valued at approximately $29,000. XTX Topco Ltd lifted its position in Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after buying an additional 31,502 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in Traws Pharma during the fourth quarter worth approximately $175,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

Wall Street Analyst Weigh In

TRAW has been the topic of a number of recent analyst reports. LADENBURG THALM/SH SH downgraded Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday, June 15th. Citigroup downgraded shares of Traws Pharma to a “neutral” rating in a research report on Monday, June 15th. Wall Street Zen upgraded shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. HC Wainwright reaffirmed a “negative” rating and issued a $1.00 target price on shares of Traws Pharma in a report on Thursday, June 18th. Finally, Weiss Ratings downgraded shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Three investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Traws Pharma has a consensus rating of “Reduce” and an average target price of $1.00.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.